Cardiac Safety Research Consortium

Sager PT, Gintant G, Turner JR, Pettit S and Stockbridge N (2014) Rechanneling the cardiac proarrhythmia safety paradigm a meeting report from the Cardiac Safety Research Consortium. Am Hearts. 167(3) 292-300. 

The Cardiac Safety Research Consortium The Power of Precompetitive Collaboration 15... 

Sager P, Heilbraun J, Turner JR et al (2013) Assessment of drug-induced increases in blood pressure during drug development report from the Cardiac Safety Research Consortium. Am Heart J 165 477-488... 

Turner JR, Kowey PR, Rodrigues I et al (2016) on behalf of the Cardiac Safety Research Consortium. The Cardiac Safety Research Consortium enters its second decade an invitation to participate. Am Heart J 177 96-101... 

Consortia are also important to the FDA s involvement in the advancement of regulatory science (Woodcock et al. 2014). Since their Critical Path Initiative was launched in 2004 (FDA 2004), FDA s Center for Drug Evaluation and Research is now participating in more than 20 science-driven consortia to improve the science of drug development and regulation (Woodcock 2014). One of these, the Cardiac Safety Research Consortium, was introduced in Chap. 1. 

The nature of the book, which is one of inclusiveness, collaboration, and integration, means that we owe a debt of gratitude to all of the researchers who conducted and reported the original research cited in the book (both in the reference lists and the Eurther Reading sections of each chapter). Many multiauthored review articles are also cited, some of which are reports from the Cardiac Safety Research Consortium thanks are expressed to all authors. 

---